

H1581 (FGFR1m NSCLC)
% of DMSO Control
1.0
0.5
0.0
-11
-10
-9
-8
-7
-6
-5
log[inhibitor]
Erdafitinib
Lerociclib
Erda + Lero (300nM)
Erda + Palbociclib (300 nM)

FIG. 1A



Snu-16 (FGFR2m gastric cancer)
% of DMSO Control
1.0
0.5
0.0
-12
-11
-10
-9
-8
-7
-6
-5
log[inhibitor]
Erdafitinib
Lerociclib
Erda + Lero (300nM)
Erda + Palbociclib (300 nM)

FIG. 1B



RT4 (FGFR3m bladder cancer)
% of DMSO Control
1.0
0.5
0.0
-11
-10
-9
-8
-7
-6
-5
log[inhibitor]
Erdafitinib
Lerociclib
Erda + Lero (300 nM)
Erda + Palbociclib (300 nM)

FIG. 1C



RT4 (FGFR 3)
Absorbance (562nm)
4
3
2
1
0
0
10
20
30
Day
DMSO
Lerociclib (300nM)
Erdafitinib (100nM)
Erdafitinib (100nM) + Lerociclib (300nM)

FIG. 2